When was Mana Therapeutics founded?

Mana Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Mana Therapeutics located?

Mana Therapeutics is headquartered in Bethesda, United States. It is registered at Bethesda (United States).

How many employees does Mana Therapeutics have?

As of Dec 31, 2021, Mana Therapeutics has 9 employees, reflecting a 10% year-over-year decline in headcount.

Is Mana Therapeutics a funded company?

Mana Therapeutics is a funded company, having raised a total of $35M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 08, 2021.

When was the latest funding round of Mana Therapeutics?

Mana Therapeutics' latest funding was a $***** Venture Debt round on Nov 30, 2021, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $909M in funding in 2026 to date.

Where does Mana Therapeutics rank among its competitors?

Mana Therapeutics ranks 1513th amongst 5185 active competitors, of which 1547 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Mana Therapeutics?

Mana Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Mana Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies for the treatment of cancer. The company uses EDIFY platform to develop cell therapies for cancer patients. The product pipeline includes MANA-312 an allogeneic donor-derived cell therapy for the treatment of acute myeloid leukemia, MANA-412 for solid tumors, and MANA-512 for multiple cancers.

Website: www.manatherapeutics.com
Registered Address: Bethesda (United States)

Key Metrics

Founded Year

2017

Location

Bethesda, United States

Stage

Deadpooled

Total Funding

$35M in 3 rounds

Latest Funding Round

Venture Debt, Nov 30, 2021, $*****

Investors

SK Securities & 6 more

Ranked

1513^th among 5185 active competitors

Employee Count

9 as on Dec 31, 2021

Similar Companies

Jazz Pharmaceuticals & 5553 more

View Mana Therapeutics' full profile

Mana Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MANA THERAPEUTICS, INC. CIN: 30-1149064 , United States, Active	Dec 18, 2017	-	9 (As on Dec 31, 2021)	-

Mana Therapeutics has raised a total funding of $35M over 3 rounds. Its first funding round was on Jan 08, 2021. Its latest funding round was a Venture Debt round on Nov 30, 2021 for $*****. 1 investor participated in its latest round. Mana Therapeutics has 7 institutional investors.

Here is the list of recent funding rounds of Mana Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 30, 2021	3488648	Venture Debt	1588300	2281043	4283188	6642409
Nov 30, 2021	6721969	Series A	7271595	2733055	3060593	4038684
Jan 08, 2021	5832875	Series A	6647578	9226266	Cobro Ventures & 1 more	LifeSci Venture Partners

Access funding benchmarks and valuations. Sign up today!

View details of Mana Therapeutics's funding rounds and investors

The founders of Mana Therapeutics are Marc A Cohen, Catherine Bollard, Patrick Hanley and C Russell Y Cruz. Marty Silverstein is the CEO of Mana Therapeutics.

Here are the details of Mana Therapeutics' key team members:

Marc A Cohen: Co-Founder of Mana Therapeutics and founder of 1 other company. They are also an angel investor in 1 startup.
Catherine Bollard: Co-Founder of Mana Therapeutics.
Patrick Hanley: Co-Founder of Mana Therapeutics.
C Russell Y Cruz: Co-Founder of Mana Therapeutics.

View details of Mana Therapeutics's Founder profiles and Board Members

Mana Therapeutics' employee count trend

Mana Therapeutics has 9 employees as of Dec 21. The total employee count is 10.0% lower than what it was in Dec 20. Here is Mana Therapeutics's employee count trend over the years:

Employee count trend for Mana Therapeutics

Uncover Mana Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mana Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Mana Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1513th	Mana Therapeutics 2017, Bethesda (United States), Deadpooled	Developer of therapies for the treatment of cancer	$35M	LifeSci Venture Partners, SVB & 5 others	38/100